Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Now Rated “Hold” by Wall Street BrokeragesDefense World · 2 days ago
Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC)Defense World · Sep 21, 2026
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) vs. Bicycle Therapeutics (NASDAQ:BCYC)Defense World · Sep 21, 2026
Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatchPYMNTS · Aug 3, 2026
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial ResultsBusiness Wire · Jul 30, 2026Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.56 | -$0.72 | Miss |
| Apr 30, 2026 | -$0.52 | -$0.87 | Miss |
| Mar 17, 2026 | -$0.94 | -$0.29 | Beat |
| Oct 30, 2025 | -$1.09 | -$0.85 | Beat |
| Aug 8, 2025 | -$0.95 | -$1.14 | Miss |
| May 1, 2025 | -$0.86 | -$0.88 | Miss |